The Endocannabinoid System May Be Involved in Huntington's, Parkinson's, Schizophrenia, and Tremor
A comprehensive review found the endocannabinoid system is involved in movement control, memory, and appetite, and may contribute to the pathology and offer therapeutic targets for Huntington's, Parkinson's, schizophrenia, and tremor.
Quick Facts
What This Study Found
This review synthesized the rapidly growing understanding of the endocannabinoid system's role in neurological disease.
The endocannabinoid system, consisting of two receptors (CB1, CB2) and two endogenous ligands (anandamide, 2-AG), is involved in normal movement control, memory formation, and appetite regulation. As this physiological role became clearer, evidence emerged that the system may be disrupted in several neurological diseases.
For Huntington's disease, loss of CB1 receptors in the basal ganglia occurs early and may contribute to the characteristic involuntary movements. For Parkinson's disease, endocannabinoid levels appear altered, and cannabinoids may help treat levodopa-induced dyskinesia. For schizophrenia, the interaction between cannabinoid and dopamine systems may contribute to psychotic symptoms. For tremor, cannabinoids showed direct therapeutic potential.
The review identified an array of potential therapeutic approaches: cannabinoid agonists, antagonists, and compounds that modify endocannabinoid synthesis, uptake, or metabolism.
Key Numbers
Two receptors (CB1, CB2). Two endogenous ligands (anandamide, 2-AG). Four diseases reviewed: Huntington's, Parkinson's, schizophrenia, tremor.
How They Did This
Comprehensive narrative review of endocannabinoid system involvement in four neurological conditions, covering receptor distribution, endocannabinoid levels, and potential therapeutic targets.
Why This Research Matters
This review reframed neurodegenerative diseases through the lens of the endocannabinoid system, suggesting that cannabis-based medicines might not just treat symptoms but address underlying pathophysiology in some conditions.
The Bigger Picture
The concept of endocannabinoid system dysfunction in neurological disease has expanded substantially since this review. Research into CB1 receptor loss in Huntington's and endocannabinoid modulation in Parkinson's continues to be active.
What This Study Doesn't Tell Us
Much of the evidence was preclinical at the time of publication. The therapeutic applications proposed were largely theoretical. The complexity of the endocannabinoid system means that simple agonist or antagonist approaches may have unintended effects.
Questions This Raises
- ?Have cannabinoid-based treatments been developed for any of these conditions?
- ?Is CB1 receptor loss a cause or consequence of Huntington's pathology?
- ?Could endocannabinoid-boosting drugs be safer than direct agonists?
Trust & Context
- Key Stat:
- CB1 receptor loss in Huntington's occurs early and may contribute to involuntary movements
- Evidence Grade:
- A comprehensive narrative review synthesizing preclinical and early clinical evidence. Provides a strong conceptual framework but many proposed applications were speculative.
- Study Age:
- Published in 2001. Research on endocannabinoid involvement in neurodegenerative diseases has expanded substantially.
- Original Title:
- The role of cannabinoids in neurodegenerative diseases.
- Published In:
- Progress in neuro-psychopharmacology & biological psychiatry, 25(4), 743-65 (2001)
- Authors:
- Glass, M
- Database ID:
- RTHC-00105
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Is the endocannabinoid system involved in neurological diseases?
Yes. This review found evidence of endocannabinoid system disruption in Huntington's, Parkinson's, schizophrenia, and tremor, suggesting both pathological involvement and therapeutic opportunities.
Could cannabis treat these diseases?
Potentially. The review identified cannabinoid agonists, antagonists, and endocannabinoid-modifying compounds as potential therapeutic approaches, though most evidence was preclinical at the time.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-00105APA
Glass, M. (2001). The role of cannabinoids in neurodegenerative diseases.. Progress in neuro-psychopharmacology & biological psychiatry, 25(4), 743-65.
MLA
Glass, M. "The role of cannabinoids in neurodegenerative diseases.." Progress in neuro-psychopharmacology & biological psychiatry, 2001.
RethinkTHC
RethinkTHC Research Database. "The role of cannabinoids in neurodegenerative diseases." RTHC-00105. Retrieved from https://rethinkthc.com/research/glass-2001-the-role-of-cannabinoids
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.